Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
- PMID: 8103403
- DOI: 10.1093/hmg/2.7.851
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Abstract
Multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC) are dominantly inherited conditions which predispose to the development of endocrine neoplasia. Evidence is presented that sequence changes within the coding region of the RET proto-oncogene, a putative transmembrane tyrosine kinase, may be responsible for the development of neoplasia in these inherited disorders. Single strand conformational variants (SSCVs) in exons 7 and 8 of the RET proto-oncogene were identified in eight MEN 2A and four FMTC families. The variants were observed only in the DNA of individuals who were either affected or who had inherited the MEN2A or FMTC allele as determined by haplotyping experiments. The seven variants identified were sequenced directly. All involved point mutations within codons specifying cysteine residues, resulting in nonconservative amino acid changes. Six of the seven mutations are located in exon 7. A single mutation was found in exon 8. Variants were not detected in four MEN 2B families studied for all exon assays available, nor were they detectable in 16 cases of well documented sporadic medullary thyroid carcinoma or pheochromocytoma that were tested for exon 7 variants. Coinheritance of the mutations with disease and the physical and genetic proximity of the RET proto-oncogene provide evidence that RET is responsible for at least two of the three inherited forms of MEN 2. Neither the normal function, nor the ligand of RET are yet known. However, its apparent involvement in the development of these inherited forms of neoplasia as well as in papillary thyroid carcinoma suggest an important developmental or cell regulatory role for the protein.
Similar articles
-
Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.Verh Dtsch Ges Pathol. 1995;79:L-LV. Verh Dtsch Ges Pathol. 1995. PMID: 8600671
-
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.Nature. 1994 Jan 27;367(6461):375-6. doi: 10.1038/367375a0. Nature. 1994. PMID: 7906866
-
[Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].Medicina (B Aires). 1998;58(2):179-84. Medicina (B Aires). 1998. PMID: 9706252 Spanish.
-
RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.Horm Res. 1997;47(4-6):168-78. doi: 10.1159/000185461. Horm Res. 1997. PMID: 9167949 Review.
-
[Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)].Schweiz Med Wochenschr. 1996 Aug 6;126(31-32):1329-38. Schweiz Med Wochenschr. 1996. PMID: 8765374 Review. German.
Cited by
-
Genetic Testing for Successful Cancer Treatment.Cureus. 2023 Dec 4;15(12):e49889. doi: 10.7759/cureus.49889. eCollection 2023 Dec. Cureus. 2023. PMID: 38179395 Free PMC article. Review.
-
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.Cancers (Basel). 2023 Oct 5;15(19):4865. doi: 10.3390/cancers15194865. Cancers (Basel). 2023. PMID: 37835559 Free PMC article. Review.
-
Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.Thorac Cancer. 2023 Nov;14(31):3166-3177. doi: 10.1111/1759-7714.15105. Epub 2023 Sep 18. Thorac Cancer. 2023. PMID: 37718634 Free PMC article.
-
Impact of Vitamin D Deficiency on Tumor Aggressiveness in Neuroendocrine Neoplasms.Nutrients. 2023 Aug 29;15(17):3771. doi: 10.3390/nu15173771. Nutrients. 2023. PMID: 37686803 Free PMC article.
-
Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.J Pers Med. 2023 Jul 13;13(7):1132. doi: 10.3390/jpm13071132. J Pers Med. 2023. PMID: 37511745 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
